

Todd E Defor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9415555/publications.pdf>

Version: 2024-02-01

40
papers

5,014
citations

623734

14
h-index

434195

31
g-index

40
all docs

40
docs citations

40
times ranked

5517
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. <i>Blood</i> , 2005, 105, 3051-3057. | 1.4 | 1,574 |
| 2 | Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. <i>Blood</i> , 2011, 117, 1061-1070. | 1.4 | 926 |
| 3 | Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. <i>Blood</i> , 2007, 110, 3064-3070. | 1.4 | 489 |
| 4 | Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 387-394. | 2.0 | 367 |
| 5 | Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. <i>Blood</i> , 2014, 123, 3855-3863. | 1.4 | 357 |
| 6 | Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. <i>Blood</i> , 2016, 127, 1044-1051. | 1.4 | 333 |
| 7 | First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. <i>Blood</i> , 2018, 131, 2515-2527. | 1.4 | 307 |
| 8 | A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 761-767. | 2.0 | 195 |
| 9 | First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1970-1980. | 5.2 | 164 |
| 10 | Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 483-494. | 4.2 | 74 |
| 11 | First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings. <i>Blood Advances</i> , 2021, 5, 1425-1436. | 5.2 | 39 |
| 12 | Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018, 2, 1882-1888. | 5.2 | 27 |
| 13 | Hematopoietic Cell Transplant-Related Toxicities and Mortality in Frail Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2454-2460. | 2.0 | 27 |
| 14 | Monosomal Karyotype at the Time of Diagnosis or Transplantation Predicts Outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 866-872. | 2.0 | 19 |
| 15 | Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease. <i>JCI Insight</i> , 2019, 4, . | 5.0 | 18 |
| 16 | Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes. <i>Blood Advances</i> , 2021, 5, 1352-1359. | 5.2 | 14 |
| 17 | Relapse Prediction Post Allogeneic Hematopoietic Cell Transplant for Myelodysplastic Syndromes Is Not Improved with Use of the More Stringent Blast Percentage Categories in the Revised International Prognostic Scoring System. <i>Blood</i> , 2012, 120, 2011-2011. | 1.4 | 14 |
| 18 | Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid. <i>Modern Pathology</i> , 2019, 32, 560-567. | 5.5 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | An Exploratory Analysis of Mitochondrial Haplotypes and Allogeneic Hematopoietic Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 81-88. | 2.0 | 9 |
| 20 | Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 56-62. | 2.0 | 9 |
| 21 | Association of Iron Overload with Survival and Complications in Allogeneic Hematopoietic Cell Transplant Recipients: Prospective Cohort Study Using R2-MRI Measured Liver Iron Content. <i>Blood</i> , 2012, 120, 1961-1961. | 1.4 | 8 |
| 22 | Infusion reactions in natural killer cell immunotherapy: a retrospective review. <i>Cytotherapy</i> , 2021, 23, 627-634. | 0.7 | 7 |
| 23 | Late-Onset Acute and Chronic Graft-versus-Host Disease in Children: Clinical Features and Response to Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 667.e1-667.e5. | 1.2 | 6 |
| 24 | Kinetics of Chimerism and Unit Predominance After Double Umbilical Cord Blood Transplantation. <i>Blood</i> , 2010, 116, 225-225. | 1.4 | 6 |
| 25 | Pulmonary Risk Factors in Allogeneic Transplantation for Hurler Syndrome.. <i>Blood</i> , 2004, 104, 2154-2154. | 1.4 | 3 |
| 26 | New Classification of Chronic Graft Versus Host Disease: Added Clarity from the Consensus Diagnoses.. <i>Blood</i> , 2007, 110, 41-41. | 1.4 | 3 |
| 27 | Predictors and outcomes of flares in chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2022, , . | 2.4 | 3 |
| 28 | High cutaneous amphiregulin expression predicts fatal acute <sc>graft-versus-host</sc> disease. <i>Journal of Cutaneous Pathology</i> , 2022, , . | 1.3 | 2 |
| 29 | Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality. <i>Blood Advances</i> , 2020, 4, 2317-2324. | 5.2 | 1 |
| 30 | Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Cerebral Variant Adrenoleukodystrophy: A Modern, Single-Institution Experience. <i>Blood</i> , 2010, 116, 3543-3543. | 1.4 | 1 |
| 31 | SEMIPARAMETRIC REGRESSION MODEL FOR RECURRENT BACTERIAL INFECTIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION. <i>Statistica Sinica</i> , 2019, 29, 1489-1509. | 0.3 | 1 |
| 32 | Prediction of outcomes after second-line treatment for acute graft-versus-host disease. <i>Blood Advances</i> , 2022, , . | 5.2 | 1 |
| 33 | Reduced Intensity Compared to High Dose Conditioning for Allotransplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Comparative Clinical Analysis.. <i>Blood</i> , 2004, 104, 1817-1817. | 1.4 | 0 |
| 34 | Acute Graft-Versus-Host Disease: Clinical Presentation and Response to Therapy Following Umbilical Cord Blood Transplant.. <i>Blood</i> , 2004, 104, 2148-2148. | 1.4 | 0 |
| 35 | Oral Bioavailability of Mycophenolate Mofetil in Patients Undergoing Nonmyeloablative Hematopoietic Cell Transplantation (HCT) Is Poor and Highly Variable.. <i>Blood</i> , 2005, 106, 842-842. | 1.4 | 0 |
| 36 | Incidence and Outcomes of Immune Thrombocytopenia (ITP) Following Hematopoietic Stem Cell Transplantation (HCT).. <i>Blood</i> , 2007, 110, 1316-1316. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Impact of Graft Source on Immune Recovery: Comparisons Between Unrelated Umbilical Cord Blood (UCB), HLA Matched Sibling (Sib) Donor and Autologous (Auto) Hematopoietic Stem Cells.. Blood, 2010, 116, 3731-3731. | 1.4 | 0 |
| 38 | Reduced Intensity Versus Myeloablative Conditioning in Adults with Acute Myeloid Leukemia Transplanted with Umbilical Cord Blood. Blood, 2010, 116, 3531-3531. | 1.4 | 0 |
| 39 | Intermittent Zoledronic Acid (ZA) for the Prevention of Osteoporosis After Allogeneic Hematopoietic Cell Transplantation (HCT). Blood, 2012, 120, 1965-1965. | 1.4 | 0 |
| 40 | Impact of CDC warning on co-prescribing of opioids and benzodiazepines in older allogeneic hematopoietic cell transplant recipients. Bone Marrow Transplantation, 2022, , . | 2.4 | 0 |